This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varghese, V.
Right arrow Articles by Shafer, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varghese, V.
Right arrow Articles by Shafer, R. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2009, p. 2196-2198, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01593-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Human Immunodeficiency Virus Type 1 Isolates with the Reverse Transcriptase (RT) Mutation Q145M Retain Nucleoside and Nonnucleoside RT Inhibitor Susceptibility{triangledown}

Vici Varghese,1,{dagger} Yumi Mitsuya,1,{dagger} Rajin Shahriar,1 Michael H. Bachmann,2 W. Jeffrey Fessel,3 Ron M. Kagan,4 and Robert W. Shafer1*

Department of Medicine, Stanford University School of Medicine, Stanford, California,1 Department of Pediatrics, Stanford University School of Medicine, Stanford, California,2 Kaiser Permanente Medical Care Program—Northern California, San Francisco, California,3 Department of Infectious Diseases, Quest Diagnostics, San Juan Capistrano, California4

Received 2 December 2008/ Returned for modification 9 January 2009/ Accepted 4 February 2009

Q145M, a mutation in a conserved human immunodeficiency virus type 1 reverse transcriptase (RT) region, was reported to decrease susceptibility to multiple RT inhibitors. We report that Q145M and other Q145 mutations do not emerge with RT inhibitors nor decrease RT inhibitor susceptibility. Q145M should not, therefore, be considered an RT inhibitor resistance mutation.

* Corresponding author. Mailing address: Division of Infectious Diseases, Room S-169, Stanford University Medical Center, Stanford, CA 94305. Phone: (650) 725-2946. Fax: (650) 725-2088. E-mail: rshafer{at}stanford.edu

{triangledown} Published ahead of print on 17 February 2009.

{dagger} These authors contributed equally.

Antimicrobial Agents and Chemotherapy, May 2009, p. 2196-2198, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01593-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»